Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10010853HBVENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS10010854HBVENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS20024833HPVENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS20065388HPVENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS20023848HPVENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS44016411HTLV-1ENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS44025476HTLV-1ENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS44000687HTLV-1ENSG00000170214.5protein_codingADRA1BNoNo147P35368
TVIS44029351HTLV-1ENSG00000170214.5protein_codingADRA1BNoNo147P35368
TCGA Plot Options
Drug Information
GeneADRA1B
DrugBank IDDB09128
Drug NameBrexpiprazole
Target IDBE0000575
UniProt IDP35368
Regulation Typeantagonist
PubMed IDs25225185; 26310190
CitationsOosterhof CA, El Mansari M, Blier P: Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014 Dec;351(3):585-95. doi: 10.1124/jpet.114.218578. Epub 2014 Sep 15.@@Greig SL: Brexpiprazole: First Global Approval. Drugs. 2015 Sep;75(14):1687-97. doi: 10.1007/s40265-015-0462-2.
GroupsApproved; Investigational
Direct ClassificationN-arylpiperazines
SMILESO=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Pathways
PharmGKBPA166160053
ChEMBLCHEMBL2105760